S*BIO has dosed the first ten patients in a Phase II clinical trial of its novel JAK2 inhibitor SB1518 for the treatment of advanced lymphoid malignancies.
The multi-centre, open-label study is designed to primarily evaluate the efficacy and safety of SB1518 in patients with advanced lymphoid malignancies such as Hodgkin’s lymphoma, mantle cell lymphoma and indolent lymphoma.
Secondary objectives include duration of response and progression-free survival.
The trial will enrol up to 87 patients, who will receive an oral 400mg dose of SB1518 daily.
The trial will be conducted at five sites across the US and Canada.
S*BIO and Onyx Pharmaceuticals have entered into development collaboration for the JAK2 inhibitors, SB1518 and SB1578.
Onyx can elect to exercise its exclusive options for SB1518 and SB1578 in all indications in the US, Canada and Europe, while S*BIO retain rights to develop and commercialise the compounds in the rest of the world.
